Jeb Bush's unfulfilled promise shows the perils of building blockbuster biotech clusters
In 2003, Jeb Bush set out to build a biotech cluster from scratch. Bush looked at the ecosystem that surrounds the Scripps Research Institute in San Diego, decided he wanted an equivalent in Florida and began throwing money at the problem. Scripps came but the predicted surge in jobs never followed. And with Bush running for president on a platform of fiscal responsibility, that could be a problem.
Scripps team finds a drug that fights addiction by eliminating memories
The memories addicts have about taking drugs tend to linger as one of the big hurdles in fighting drug addiction, constantly beckoning an addict to re-experience the highs that got him hooked in the first place. But a team of researchers at Scripps' Florida campus set out to find a drug that could selectively extinguish those memories, and just took a big step toward getting a therapy in the clinic.
Antibody 'cocktail' looks promising against deadly Marburg virus
In a recent study, scientists at The Scripps Research Institute have characterized new antibodies that protect against the ebolavirus' sinister relative--the Marburg virus.
Scripps spotlights PPARγ inhibitor as a potential drug for bone loss
A team of scientists from The Scripps Research Institute led by Dr. Patrick Griffin has observed for the first time that a novel compound may help promote bone formation in patients afflicted with bone loss.
Scripps Parkinson's study points to a key enzyme as a potential drug target
A team of investigators at the Florida branch of Scripps Research Institute says that a little-understood enzyme known as serum glucocorticoid kinase 1 could play a role in preventing or treating Parkinson's disease.
Stem cell advance may assist new therapies for anemia, leukemia
Scientists at the Scripps Research Institute say they've identified an enzyme necessary for maintaining the stability of hematopoietic stem cells.
Mayo/Scripps team begins testing a new class of anti-aging drugs
Investigators have begun testing new drugs that can specifically hunt down and eliminate senescent cells in mice, opening the door to what they say could be a new class of therapeutics that promise to one day slow down the human aging process.
Scripps investigators ID a key player in disarming chemotherapy
Multidrug resistance to the chemotherapies in wide use today is a lethal problem. As patients stop responding to drugs, they become increasingly vulnerable to a deadly assault. Now investigators at The Scripps Research Institute say they have illuminated a key protein that plays a big role in promoting drug resistance, offering a new approach for investigators designing the next generation of new and improved cancer therapies that won't eventually be disarmed.
Scripps investigators refine new drugs for Parkinson's disease
The Florida branch of The Scripps Research Institute is touting some new advances related to Parkinson's disease. Researchers say they have been working on new therapies that can precisely hit pathways critical for the death of brain cells, a hallmark of the disease. And they're now fine tuning their work by focusing on the oral bioavailability of their new drug candidates.
Team takes a new approach to taming neuroinflammation
A team at Scripps is identifying enzymes that influence production of an inflammatory lipid molecule in the brain, offering a prime target for drug developers and insights that may also assist investigators in fields involving brain inflammation, such as multiple sclerosis, Alzheimer's, Parkinson's and ALS.